Key Insights

Highlights

Success Rate

58% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 87/100

Termination Rate

36.4%

8 terminated out of 22 trials

Success Rate

57.9%

-28.6% vs benchmark

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

45%

5 of 11 completed with results

Key Signals

5 with results58% success

Data Visualizations

Phase Distribution

20Total
Not Applicable (1)
Early P 1 (2)
P 1 (10)
P 2 (6)
P 3 (1)

Trial Status

Completed11
Terminated8
Withdrawn2
Unknown1

Trial Success Rate

57.9%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (22)

Showing 20 of 20 trials
NCT01814501Phase 2Completed

Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab

NCT01652196Phase 2Completed

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

NCT02132858CompletedPrimary

Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation

NCT02232152Phase 1Completed

CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

NCT03693846Phase 2Terminated

Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors

NCT01871571Phase 2UnknownPrimary

Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer

NCT01285102Phase 1Terminated

Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer

NCT02270606Phase 1CompletedPrimary

Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer

NCT01643499Phase 1Completed

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

NCT01923337Phase 1Completed

Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

NCT01197664Phase 1TerminatedPrimary

Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery

NCT02110953Phase 1Terminated

Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver

NCT01934179Terminated

Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy

NCT01726296Not ApplicableCompleted

Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care

NCT02235324Phase 2Withdrawn

Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer

NCT00835679Early Phase 1Terminated

Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery

NCT01403103Early Phase 1Withdrawn

Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer

NCT00060411Phase 1Completed

A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer

NCT00005036Phase 3Completed

Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

NCT00002796Phase 1Terminated

Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer

Scroll to load more

Research Network

Activity Timeline